Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Stock Information for Tenax Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tenax Therapeutics Inc.

Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
Tenax Therapeutics to Participate in Upcoming Investor Conferences
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.